Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
ID: 347718Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347718

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program seeks to support innovative projects that enhance the prevention, diagnosis, treatment, and care for individuals affected by AD/ADRD, while also addressing the shortage of scientists in this critical research area. Eligible applicants include a wide range of institutions, such as higher education institutions, community-based organizations, and tribal colleges, with funding of up to $100,000 per year available for projects lasting a maximum of two years. Applications are accepted on a rolling basis until March 17, 2026, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-179-Full-Announcement.html
    PAR-23-179.html
    The National Institutes of Health (NIH) has reissued the Small Research Grant Program (R03) targeting emerging researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The program aims to stimulate innovative research to enhance prevention, diagnosis, treatment, and caregiving for individuals with AD/ADRD while addressing the shortage of scientists in this critical area. The program encourages applications from early stage investigators and researchers lacking major prior funding in the field. Funding of up to $100,000 per year is available for projects lasting a maximum of two years, with an anticipated total of 12 awards worth $1.8 million in fiscal year 2024. Application submissions are due every few months, starting from July 19, 2023, until March 17, 2026. Various research topics are encouraged, ranging from understanding the disease trajectory and identifying health disparities to exploring molecular pathways and behavioral interventions. Eligibility extends to numerous institutional types, including higher education institutions and non-profits. Applications must adhere strictly to specified guidelines, and submissions must be made electronically through the NIH's platform. This initiative reflects NIH's strategic goals to build a diverse workforce equipped to tackle AD/ADRD research challenges.
    Similar Opportunities
    Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity through the Small Research Grant Program (R03) aimed at supporting junior faculty researchers in low- and middle-income countries (LMICs) who are focused on aging, Alzheimer's Disease (AD), and AD-related dementias (ADRD). This initiative encourages applications from eligible institutions within LMICs, with the objective of fostering research capacity and career development for junior investigators in these regions. Given the projected increase in older populations and the rising incidence of AD/ADRD in LMICs, this program is critical for addressing global health challenges. Interested applicants can apply for grants of up to $100,000 per year, with a submission deadline of February 14, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing research on Alzheimer's Disease (AD) and AD-related dementias (ADRD) through the Small Business Innovation Research (SBIR) program. This initiative invites U.S. small businesses to submit applications for innovative research projects that could lead to new therapies, diagnostic technologies, or prevention strategies for AD/ADRD. The funding reflects a significant federal commitment to addressing the challenges posed by these conditions, with a total of $20 million anticipated for approximately 40 awards in 2023, providing up to $500,000 for Phase I and $2.5 million for Phase II projects. Interested applicants can find more details and application requirements at the provided link and should note that the application deadline is September 5, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research grant applications for the "Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" initiative. This funding opportunity aims to collect pilot data to support early-stage testing of both pharmacological and non-pharmacological interventions targeting cognitive and neuropsychiatric changes associated with Alzheimer's Disease (AD) and related dementias (ADRD). The initiative is crucial in addressing the public health crisis posed by these conditions, emphasizing the need for effective therapies and improved trial designs. Interested applicants can apply for grants with an award ceiling of $325,000, with applications due by November 18, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Functional Target Validation for Alzheimer’s Disease-Related Dementias (ADRD) through a phased R61/R33 grant program. This initiative aims to support the comprehensive functional validation of therapeutic target candidates identified via genetic or tissue analysis in human samples, with a focus on developing technologies and models to assess their effects. The program is critical in addressing the urgent need for novel therapeutic strategies for ADRD, which includes disorders such as frontotemporal degeneration and vascular contributions to cognitive impairment. Interested applicants, including academic institutions and community-based organizations, must submit their proposals by November 8, 2024, and can find further details at the NIH grants website or contact grantsinfo@nih.gov for inquiries.